LEADER 01239nam0-2200349---450- 001 990009896520403321 005 20140918122052.0 010 $a978-88-8207-542-2 035 $a000989652 035 $aFED01000989652 035 $a(Aleph)000989652FED01 035 $a000989652 100 $a20140918d2014----km-y0itay50------ba 101 0 $aita 102 $aIT 105 $aaf--j---001yy 200 1 $aConsolidamento strutture in muratura$emetodi e tecniche di intervento per edifici esistenti in muratura portante : aggiornato all'ordinanza C.D.P.C. 20 febbraio 2013, n. 52 relativa ai contributi per gli interventi di prevenzione del rischio sismico$fGiuliano Vecchi, Marco Giovannelli 210 $aPalermo$cGrafill$dİ2014 215 $aVI, 167 p.$cill.$d24 cm 225 1 $aManuali$v152 300 $aCon il servizio G-cloud si riceve il software 610 0 $aEdifici$aConsolidamento e strutture 676 $a693.1 700 1$aVecchi,$bGiuliano$0523698 701 1$aGiovannelli,$bMarco$0523699 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990009896520403321 952 $aTECN B 2008$b21240$fFARBC 959 $aFARBC 996 $aConsolidamento strutture in muratura$9829003 997 $aUNINA LEADER 04112nam 2200913z- 450 001 9910619470303321 005 20221025 010 $a3-0365-5390-8 035 $a(CKB)5670000000391571 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/93224 035 $a(oapen)doab93224 035 $a(EXLCZ)995670000000391571 100 $a20202210d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aUpdates in Management of SARS-CoV-2 Infection 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 online resource (198 p.) 311 08$a3-0365-5389-4 330 $aSevere acute respiratory syndrome coronavirus 2 (SARS?CoV?2) has spread worldwide from the beginning of 2020. The infection is mostly asymptomatic but some patients may develop COVID?19 (coronavirus disease 2019) with a severe or critical course leading to pneumonia, acute respiratory distress syndrome, and multiorgan failure. Apart from the virus?related damage of the lungs, pathomechanism of the disease seems to be linked to thromboembolism and inflammation accompanied by overproduction of proinflammatory cytokines, termed a cytokine storm, responsible for multiorgan damage and death. Since the development of a new therapeutic molecule, dedicated strictly to a particular virus is time?consuming, physicians and scientists have started to test and repurpose old medications. Unfortunately, after one year of pandemics, there is still a lack of optimal therapy and no clear indicators of recovery. A major issue is also insufficient knowledge on predictors of the severe or deadly course of the disease, which could also help to switch from one therapeutic option to another. Due to many gaps still existing in the management of COVID-19, there is a need for the accumulation of new data particularly from real-world experience, which could be applicable to practice guidelines. The objective of this special issue of the Journal of Clinical Medicine is to provide an update on the mangement for the diagnostic workup and pharmacotherapy of SARS?CoV?2 infection. 606 $aMedicine$2bicssc 610 $aangiotensin 1 receptor (AT1R) 610 $aangiotensin II 610 $aantigen detection 610 $aartificial intelligence 610 $aAT1R concentration 610 $aCharlson Comorbidities Index 610 $achildren 610 $aclinical outcome 610 $aclinical presentation 610 $acluster analysis 610 $aco-infections 610 $acoronavirus disease 2019 610 $acoronavirus disease 2019 (COVID-19) 610 $aCOVID-19 610 $aCOVID-19 diagnosis 610 $aCOVID-19 pneumonia 610 $acritical care 610 $acytokines 610 $aCytomegalovirus 610 $adiagnosis 610 $aepidemiology 610 $aindividualized management 610 $ainflammation 610 $ainterleukin-6 610 $akidney failure 610 $aliver functional tests 610 $aliver markers 610 $alongitudinal cluster 610 $amedical imaging 610 $ameta-analysis 610 $amethodological credibility 610 $amorbidity 610 $amortality 610 $an/a 610 $apandemic 610 $aPCR test 610 $apersonalized medicine 610 $aprognosis 610 $arapid diagnostic test 610 $aSARS-CoV-2 610 $asevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 610 $aseverity 610 $asymptomatology 610 $asymptoms' severity 610 $asystematic umbrella review 610 $atherapy 610 $atocilizumab 610 $atrial sequential analysis 615 7$aMedicine 700 $aFlisiak$b Robert$4edt$01328782 702 $aFlisiak$b Robert$4oth 906 $aBOOK 912 $a9910619470303321 996 $aUpdates in Management of SARS-CoV-2 Infection$93038948 997 $aUNINA